Abstract
Background: Direct inhibition of coagulation factor XIa (FXIa) carries a significant promise for developing effective and safe anticoagulants.
Method: In this report, we studied 4-methyl-2-oxo-2H-chromen-7-yl furan-2-carboxylate 1, a coumarin derivative, for direct FXIa inhibition.
Results: This small molecule was found to inhibit FXIa with an IC50 value of 0.77 µM. Coumarin 1 also displayed a moderate-to-high selectivity for FXIa inhibition over other coagulation, digestive, and fibrinolysis serine proteases. Coumarin 1 selectively doubled APTT of human plasma at a concentration of 72 µM. Insights about the structural features that contribute to the unique potential of such small molecule were deduced by profiling similar molecules in PubChem Open Chemistry Database as well as by performing a computational docking exercise.
Conclusion: Overall, chromen-7-yl furan-2-carboxylate 1 is expected to serve as an excellent fragmental lead for further anticoagulant design and development.
Keywords: Factor XIa, anticoagulant, coumarin, active site inhibitor, clotting times, direct inhibition.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Volume: 15 Issue: 1
Author(s): Ahmad J. Obaidullah and Rami A. Al-Horani*
Affiliation:
- 1 Drexel Drive, College of Pharmacy, Suite 327, Xavier University of Louisiana, New Orleans, LA 70125,United States
Keywords: Factor XIa, anticoagulant, coumarin, active site inhibitor, clotting times, direct inhibition.
Abstract: Background: Direct inhibition of coagulation factor XIa (FXIa) carries a significant promise for developing effective and safe anticoagulants.
Method: In this report, we studied 4-methyl-2-oxo-2H-chromen-7-yl furan-2-carboxylate 1, a coumarin derivative, for direct FXIa inhibition.
Results: This small molecule was found to inhibit FXIa with an IC50 value of 0.77 µM. Coumarin 1 also displayed a moderate-to-high selectivity for FXIa inhibition over other coagulation, digestive, and fibrinolysis serine proteases. Coumarin 1 selectively doubled APTT of human plasma at a concentration of 72 µM. Insights about the structural features that contribute to the unique potential of such small molecule were deduced by profiling similar molecules in PubChem Open Chemistry Database as well as by performing a computational docking exercise.
Conclusion: Overall, chromen-7-yl furan-2-carboxylate 1 is expected to serve as an excellent fragmental lead for further anticoagulant design and development.
Export Options
About this article
Cite this article as:
Obaidullah J. Ahmad and Al-Horani A. Rami *, Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor, Cardiovascular & Hematological Agents in Medicinal Chemistry 2017; 15 (1) . https://dx.doi.org/10.2174/1871525715666170529093938
DOI https://dx.doi.org/10.2174/1871525715666170529093938 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Editorial [Hot Topic: New Medicinal Chemistry Approaches for the Treatment of Cardiovascular Disease (Guest Editor: Dennis Lee)]
Current Topics in Medicinal Chemistry Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Erectile Dysfunction and Diabetes Mellitus: Mechanistic Considerations from Studies in Experimental Models
Current Diabetes Reviews A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Pneumonia in the Elderly
Current Respiratory Medicine Reviews Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease: From Clinical Trials to Daily Practice
Reviews on Recent Clinical Trials Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine The Interaction of Depression and Diabetes: A Review
Current Diabetes Reviews The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Community Expansion and Gene Geography of Sickle Cell Trait and G6PD Deficiency, and Natural Selection against Malaria: Experience from Tribal Land of India
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Understanding and Modulating the Toll Like Receptors (TLRs) and NOD Like Receptors (NLRs) Cross Talk in Type 2 Diabetes
Current Diabetes Reviews Headspace Analyses in Valuable and Functional Foods: Application of SPME in the Quality Control and Characterization of Olive Oils
Current Analytical Chemistry Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry